Page last updated: 2024-12-08

keratan sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Keratan Sulfate: A sulfated mucopolysaccharide initially isolated from bovine cornea. At least two types are known. Type I, found mostly in the cornea, contains D-galactose and D-glucosamine-6-O-sulfate as the repeating unit; type II, found in skeletal tissues, contains D-galactose and D-galactosamine-6-O-sulfate as the repeating unit. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

keratan sulfate : A sulfated glycosaminoglycan, a linear polymer that consists of the repeating disaccharide [3)-beta-Gal-(1->4)-beta-GlcNAc-(1->] and containing sulfo groups located at random positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

keratan 6'-sulfate : A keratan sulfate with random sulfation at the 6'-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID446715
MeSH IDM0011943

Synonyms (10)

Synonym
KERATAN ,
keratan 6'-sulfate
kerato 6'-sulfate
kerato sulfate
keratan sulfate
{[(2s,4s,5r,6s)-5-acetamido-6-{[(2s,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-[(sulfooxy)methyl]-6-{[(2r,3r,4s,5s,6r)-2,3,5-trihydroxy-6-[(sulfooxy)methyl]oxan-4-yl]oxy}oxan-3-yl]oxy}-3,5-dihydroxy-6-[(sulfooxy)methyl]oxan-4-yl]oxy}-4-hydr
kerato sulphate
kerato 6'-sulphate
keratan 6'-sulphate
keratan sulphate

Research Excerpts

Overview

Keratan sulfate (KS) is an abundant proteoglycan in the developing human CNS. It functions as an extracellular axonal guidance molecule, repelling glutamatergic while facilitating GABAergic axons. Keratan sulfATE is a glycosaminoglycan that has been investigated in the cornea and skeletal tissues for decades.

ExcerptReferenceRelevance
"Keratan sulfate (KS) is a functional electrosensory and neuro-instructive molecule. "( Functional Consequences of Keratan Sulfate Sulfation in Electrosensory Tissues and in Neuronal Regulation.
Melrose, J, 2019
)
2.25
"Keratan sulfate (KS) is an abundant proteoglycan in the developing human CNS where it functions as an extracellular axonal guidance molecule, repelling glutamatergic while facilitating GABAergic axons. "( Keratan sulfate proteoglycan as an axonal insulating barrier in the forebrain of fetuses with alobar/semi-lobar holoprosencephaly.
Flores-Sarnat, L; Sarnat, HB; Yu, W,
)
3.02
"Keratan sulfate (KS) is a carbohydrate side chain covalently attached to extracellular proteoglycans. "( GlcNAc6ST3 is a keratan sulfate sulfotransferase for the protein-tyrosine phosphatase PTPRZ in the adult brain.
Akama, TO; Foyez, T; Kadomatsu, K; Kato, K; Komatsu, Y; Takeda-Uchimura, Y; Uchimura, K; Yagi, H; Zhang, Z, 2019
)
2.3
"Keratan sulfate (KS) is a sulfated linear polymer of N-acetyllactosamine. "( Role of keratan sulfate expression in human pancreatic cancer malignancy.
Grandgenett, PM; Leiphrakpam, PD; Patil, PP; Qiu, F; Radhakrishnan, P; Remmers, N; Swanson, B; Yu, F, 2019
)
2.39
"Keratan sulfate (KS) is an important glycosaminoglycan that is found in cartilage, reproductive tissues, and neural tissues. "( Isolation of bovine corneal keratan sulfate and its growth factor and morphogen binding.
Li, L; Linhardt, RJ; Solakyildirim, K; Weyers, A; Yang, B; Yee, V; Zhang, F, 2013
)
2.13
"Keratan sulfate (KS) is a glycosaminoglycan (GAG) type consisted of a sulfated poly-N-acetyl lactosamine chain. "( Keratan sulfate: an up-to-date review.
Pomin, VH, 2015
)
3.3
"Keratan sulfate is a glycosaminoglycan that has been investigated in the cornea and skeletal tissues for decades. "( Keratan sulfate: biosynthesis, structures, and biological functions.
Uchimura, K, 2015
)
3.3
"Keratan sulfate (KS) is a glycosaminoglycan that is included in the KSPG that acts as an inhibitory factor in nerve regeneration after CNS injury."( Keratan sulfate exacerbates experimental autoimmune encephalomyelitis.
Kadomatsu, K; Kusunoki, S; Miyamoto, K; Moriguchi, K; Tanaka, N; Ueno, R, 2015
)
2.58
"Keratan sulfate (KS) is a sulfated glycosaminoglycan and has been shown to bind to sonic hedgehog (Shh), which act as a morphogen to regulate the embryonic spinal cord development. "( Keratan Sulfate Regulates the Switch from Motor Neuron to Oligodendrocyte Generation During Development of the Mouse Spinal Cord.
Hashimoto, H; Ikenaka, K; Ishino, Y; Jiang, W; Kadomatsu, K; Takeda-Uchimura, Y; Uchimura, K; Yoshimura, T, 2016
)
3.32
"Keratan sulfate is a glycosaminoglycan found in the structure of cartilage proteoglycans, aggrecan and fibromodulin. "( Immunological detection of keratan sulfate in meat products with and without mechanically separated chicken meat.
Betti, M; Nakano, T; Ozimek, L, 2012
)
2.12
"Keratan sulfate is an inert material, and hazardous effects due to its presence in these formulations are unlikely to occur."( Residual keratan sulfate in chondroitin sulfate formulations for oral administration.
Mourão, PA; Pereira, MS; Piquet, AA; Pomin, VH, 2012
)
1.52
"Keratan sulfate (KS) is a glycosaminoglycan consisting of repeating disaccharide units composed of alternating residues of d-galactose and N-acetyl-d-glucosamine linked beta-(1-4) and beta-(1-3), respectively. "( Analysis of keratan sulfate oligosaccharides by electrospray ionization tandem mass spectrometry.
Conrad, AH; Conrad, GW; Kariya, Y; Tasheva, ES; Zhang, Y, 2005
)
2.15
"Keratan sulfate (KS) is a glycosaminoglycan composed of repeating disaccharide units with sulfate residues at the C6 positions of galactose and N-acetylglucosamine (GlcNAc). "( N-Acetylglucosamine 6-O-sulfotransferase-1 is required for brain keratan sulfate biosynthesis and glial scar formation after brain injury.
Kadomatsu, K; Muramatsu, T; Murase, A; Uchimura, K; Yuasa, S; Zhang, H, 2006
)
2.01
"Keratan sulfate is a functional substitute for chondroitin sulfate in O2-deficient tissues."( Structure and biological functions of keratan sulfate proteoglycans.
Greiling, H, 1994
)
1.28
"Keratan sulfate (KS) is a glycosaminoglycan, distribution of which is confined mostly to hyaline cartilage. "( Keratan sulfate as a marker of articular cartilage catabolism and joint treatment in ponies.
Freeman, KP; Lust, G; Parente, EJ; Todhunter, RJ; Yeager, AE, 1993
)
3.17
"Keratan sulfate is a major constituent of proteoglycans."( In vivo detection of intervertebral disk injury using a radiolabeled monoclonal antibody against keratan sulfate.
Grönblad, M; Hyytinen, T; Kääpä, E; Kairemo, KJ; Karonen, SL; Laitinen, OM; Lappalainen, AK, 2001
)
1.25

Toxicity

ExcerptReferenceRelevance
"Bevacizumab is not toxic to corneal cells of human origin in vitro at doses usually used for treatment of corneal neovascularization, which is 20-fold higher than that used for intravitreal application."( Safety profile of bevacizumab on cultured human corneal cells.
Aisenbrey, S; Bartz-Schmidt, KU; Spitzer, MS; Szurman, P; Tatar, O; Yoeruek, E, 2007
)
0.34
"8%) administered led to adverse events (AEs) requiring infusion interruption and medical intervention."( Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
Bialer, M; Harmatz, P; Jones, SA; Martin, K; Parini, R; Shaywitz, AJ; Wang, H; Yang, K, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" Lumican expression was negatively correlated with the basal level of Smad 2 activation in these cells, suggesting that lumican may affect the bioavailability of Smad 2 activators."( Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells.
Berdiaki, A; Karamanos, NK; Katonis, P; Nikitovic, D; Tsatsakis, A; Tzanakakis, GN; Zafiropoulos, A, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
"8)m in all patients combined, regardless of dosing regimen, for the ITT and MPP populations, respectively."( Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
AlSayed, MD; Berger, KI; Burton, BK; Giugliani, R; Guelbert, N; Harmatz, PR; Hendriksz, CJ; Hughes, DA; Jurecki, E; Matousek, R; Mitchell, JJ; Parini, R; Raiman, J; Shaywitz, AJ; Slasor, P; Solano Villarreal, ML; Stewart, F, 2016
)
0.43
" As revealed by heatmap and principal component analysis, the mice gut microbiota was readily altered at different taxonomic levels by intake of low (8 mg/kg) and high dosage (40 mg/kg) of KS."( Dietary Keratan Sulfate from Shark Cartilage Modulates Gut Microbiota and Increases the Abundance of Lactobacillus spp.
Cai, C; Hao, J; Jiang, H; Li, G; Li, Q; Shang, Q; Shi, J; Song, G; Yu, G; Zhang, M, 2016
)
0.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
11p11.2 copy number variation syndrome216

Research

Studies (1,451)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990353 (24.33)18.7374
1990's452 (31.15)18.2507
2000's352 (24.26)29.6817
2010's261 (17.99)24.3611
2020's33 (2.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.35 (24.57)
Research Supply Index7.32 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index89.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (1.54%)5.53%
Reviews103 (6.90%)6.00%
Case Studies33 (2.21%)4.05%
Observational1 (0.07%)0.25%
Other1,332 (89.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]